Sangamo Therapeutics (SGMOQ) EBITDA (2010 - 2025)

Sangamo Therapeutics has reported EBITDA for 16 years, with the latest figure at -$38.2 million in Q4 2025.

• On a quarterly basis, EBITDA fell 46.99% year-over-year to -$38.2 million in Q4 2025; TTM through Dec 2025 was -$121.2 million, a 16.61% decrease from a year earlier, with the FY2025 full-year figure at -$121.2 million, down 16.61% from the prior year.
• EBITDA was -$38.2 million for Q4 2025 at Sangamo Therapeutics, down from -$35.6 million in the prior quarter.
• The five-year high for EBITDA was $18.0 million in Q1 2023, with the low at -$123.6 million in Q2 2023.
• Average EBITDA over 5 years is -$44.2 million, with a median of -$45.5 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: EBITDA sank 1208.73% in 2021, then jumped 139.84% in 2023.
• Over 5 years, EBITDA stood at -$39.9 million in 2021, then plunged by 38.83% to -$55.4 million in 2022, then retreated by 12.04% to -$62.1 million in 2023, then jumped by 58.12% to -$26.0 million in 2024, then plunged by 46.99% to -$38.2 million in 2025.
• The last three EBITDA figures came in at -$38.2 million (Q4 2025), -$35.6 million (Q3 2025), and -$17.9 million (Q2 2025), per Business Quant data.